4-((4-hydroxybut-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide | 1068657-02-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((4-hydroxybut-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide
• 英文别名: 4-[2-oxido-3-(phenylsulfonyl)-1,2,5-oxadiazol-4-yloxy]but-2-en-1-ol；4-[[4-(benzenesulfonyl)-5-oxido-1,2,5-oxadiazol-5-ium-3-yl]oxy]but-2-en-1-ol
• CAS: 1068657-02-2
• 化学式: C₁₂H₁₂N₂O₆S
• 分子量: 312.303
• InChiKey: SRFBPUYTJRYEMY-UHFFFAOYSA-N

物化性质

• 熔点：
  72-74 °C
• 沸点：
  583.3±60.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.07
• 重原子数：
  21.0
• 可旋转键数：
  6.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  116.57
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  4-((4-hydroxybut-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 在 四溴化碳 、 potassium carbonate 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  二十碳五烯苷A1的一氧化氮供体衍生物：作为潜在抗癌药的体内和体外合成及生物学评估。

  摘要：

  设计，合成和评估了一系列带有三萜皂苷基序的二十碳五烯苷A1的一氧化氮（NO）捐赠衍生物。所有测试的基于呋喃喃的NO释放化合物均显示出显着的增殖抑制活性。尤其是化合物6a在体外对四种人类肿瘤细胞系（SMMC-7721，NCI-H460，U251，HCT-116）表现出强大的细胞毒性（IC50 =1.6-6.5μM），并具有最高水平的NO释放。此外，化合物6a显示出对小鼠的低急性毒性和弱的溶血活性，并且在体内对小鼠H22肝细胞具有有效的肿瘤生长抑制作用（51.5％）。

  DOI：

  10.1016/j.bmcl.2016.11.021
• 作为产物：
  描述：

  苯硫基乙酸 在 双氧水 、 溶剂黄146 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 8.0h， 生成 4-((4-hydroxybut-2-en-1-yl)oxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide
  参考文献：
  名称：

  Aurover tin B衍生物及其制备方法与应用

  摘要：

  本发明提供了一种aurovertin B衍生物和aurovertin B衍生物的制备方法，以及aurovertin B衍生物在制备治疗三阴乳腺癌的药物中的应用。本发明所述的aurovertin B衍生物极性得到明显提高，有利于制剂和体内生物利用度的提高；具有更好的成药性；另外，本发明所述的aurovertin B衍生物与aurovertin B相比，化合物的活性得到了提高，并降低了对正常细胞的毒性，提高其成药性。因此aurovertin B衍生物在制备治疗三阴乳腺癌的药物中有极好的应用前景，特别是三阴乳腺癌细胞为HCC1937细胞和MDA‑MB‑231细胞时药效活性极佳。

  公开号：

  CN112094278B

文献信息

• Design and synthesis of novel senkyunolide analogues as neuroprotective agents
  作者：Yuanying Fang、Rikang Wang、Qi Wang、Yongbing Sun、Saisai Xie、Zunhua Yang、Min Li、Yi Jin、Shilin Yang

  DOI：10.1016/j.bmcl.2018.01.018

  日期：2018.2

  A class of senkyunolide analogues bearing benzofuranone fragment were designed, synthesized and evaluated for their neuroprotective effect in models of oxygen glucose deprivation (OGD) and oxidative stress. All tested compounds showed neuroprotection profile based on the cell viability assay. In particular, derivatives 1f–1i possessing furoxan-based nitric oxide releasing functionality exhibited significant

  设计，合成并评估了一类带有苯并呋喃酮片段的senkyunolide类似物在氧葡萄糖剥夺（OGD）和氧化应激模型中的神经保护作用。基于细胞活力测定法，所有测试的化合物均显示出神经保护作用。特别是，具有基于呋喃喃的一氧化氮释放功能的衍生物1f – 1i在OGD模型中表现出显着的生物学活性。更重要的是，含有短接头与呋喃喃的化合物1g在浓度为100μM时显示出最有效的神经保护作用（细胞存活率高达145.2％）。此外，1g在氧化应激模型中也表现出中等水平的神经保护作用。
• Synthesis and Biological Study of 3-Butyl-1-(2,6-dichlorophenyl)-1H-[1,2,4]triazol- 5(4H)-one Derivatives as Anti-hypertension Drugs
  作者：Yanchun Zhang、Jinpei Zhou、Weihong Pan、Xiaoming Wu、Shuai Wang

  DOI：10.2174/157018010789869370

  日期：2010.1.1

  A series of nitric oxide-donating derivatives of [1,2,4]triazol-5(4H)-one (9a-f and 15a-f) as a novel class of angiotensin II receptor AT1 antagonists have been designed and synthesized by coupling furoxan and nitric oxide with lead compound 1. The synthesized compounds were evaluated for their antagonism of AT1 receptor with induced contraction in the rabbit thoracic aortic ring and the results showed that compounds 9b, 15b and 15d exhibited potent antagonistic activity of AT1 receptor. Moreover 9b, 15b, 15d, 15e had good maximum NO release amount of this series.

  一系列新型血管紧张素II受体AT1拮抗剂——[1,2,4]三唑-5(4H)-酮（9a-f和15a-f）的硝酸氧化物衍生物，通过将呋喃并氧和硝酸氧化物与前导化合物1结合而设计并合成。合成的化合物在兔胸主动脉环中诱导收缩的情况下，对其AT1受体的拮抗作用进行了评估，结果显示化合物9b、15b和15d展现出强大的AT1受体拮抗活性。此外，9b、15b、15d、15e在这一系列化合物中具有良好的最大NO释放量。
• Synthesis and Biological Evaluation of Nitric Oxide-Donating Thalidomide Analogues as Anticancer Agents
  作者：Tao Wang、Yi-Hua Zhang、Xiang-Wen Kong、Yi-Sheng Lai、Hui Ji、Yan-Ping Chen、Si-Xun Peng

  DOI：10.1002/cbdv.200800014

  日期：2009.4

  In search of more potent anticancer agents, 15 nitric oxide (NO)-donating thalidomide analogues, 6a, 6b, 8a-8e, and 13a-13h, were designed and synthesized. Cytotoxicity of these compounds was evaluated in vitro against three human tumor cell lines (HepG2, A549, and PC-3). The results indicated that 13a-13d exhibited notable anticancer activities comparable to or stronger than that of 5-fluorouracil

  为了寻找更有效的抗癌剂，设计并合成了 15 种一氧化氮 (NO) 供体沙利度胺类似物 6a、6b、8a-8e 和 13a-13h。这些化合物对三种人类肿瘤细胞系（HepG2、A549 和 PC-3）的体外细胞毒性进行了评估。结果表明，13a-13d表现出与5-氟尿嘧啶(5-FU)相当或更强的显着抗癌活性。根据获得的实验数据，还讨论了构效关系。通常，目标化合物的细胞毒活性与 NO 供体的类型密切相关，连接到 NO 供体的间隔物的长度对生物活性也很重要。
• Synthesis and Bioactivity of Furoxan-Based Nitric Oxide-Releasing Colchicine Derivatives as Anticancer Agents
  作者：Li Hong Shen、Sheng Li Wang、Hong Yu Li、Yi Sheng Lai、Li Jie Liu

  DOI：10.14233/ajchem.2013.13635

  日期：——

  A series of novel nitric oxide-donating colchicine derivatives (9a-j) were synthesized by coupling furoxan with N-methyl colchiceinamide through an appropriate spacer arm and their cytotoxicity against four human cancer cell lines in vitro were evaluated by MTT method. It was found that many of the derivatives displayed significant activity, particularly, compound 9f showed more potent cytotoxic activities than colchicine.

  通过将呋喃并[1,2-a]唑酮与N-甲基秋水仙酰胺通过适当的间隔臂偶联，合成了一系列新的NO供体型秋水仙碱衍生物（9a-j），并采用MTT法评估了它们对四种人癌细胞系的体外细胞毒性。结果发现，许多衍生物表现出显著的活性，特别是化合物9f的细胞毒性活性显著强于秋水仙碱。
• Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents
  作者：Yisheng Lai、Lihong Shen、Zhenzhen Zhang、Wenqing Liu、Yihua Zhang、Hui Ji、Jide Tian

  DOI：10.1016/j.bmcl.2010.09.070

  日期：2010.11

  A series of novel furoxan-based nitric oxide (NO)-releasing derivatives of glycyrrhetinic acid (GA) were designed, synthesized, and evaluated for their in vitro cytotoxicity against human hepatocellular carcinoma (HCC) and non-tumor liver cells. Five furoxan/GA hybrids, 7b-d, 7f, and 7g, displayed potent cytotoxicity against HCC cells (IC(50): 0.25-1.10 mu M against BEL-7402 cells and 1.32-6.78 mu M against HepG2 cells), but had a little effect on the growth of LO2 cells, indicating that these compounds had selective cytotoxicity against HCC cells. Furthermore, these compounds produced high concentrations of NO in HCC cells, but low in LO2 cells and treatment with hemoglobin partially reduced the cytotoxicity of the hybrid in HCC cells. Apparently, the high concentrations of NO produced by NO donor moieties and the bioactivity of GA synergistically contribute to the cytotoxicity, but the NO is a major player against HCC cells in vitro. Potentially, our findings may aid in the design of new chemotherapeutic reagents for the intervention of human HCC at clinic. (C) 2010 Elsevier Ltd. All rights reserved.